Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. more
Time Frame | CRDL | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.68% | -3.35% | -2.97% |
1-Month Return | -20.61% | -3.49% | -0.66% |
3-Month Return | -41.78% | -12.6% | 2.71% |
6-Month Return | -30.69% | -6.91% | 7.21% |
1-Year Return | 51.8% | 1.19% | 23.04% |
3-Year Return | -33.84% | -0.21% | 28.43% |
5-Year Return | -57.33% | 33.09% | 82.88% |
10-Year Return | -64.99% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 78.76K | 78.76K | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 150.57K | 229.54K | - | 219.91K | 248.35K | [{"date":"2019-12-31","value":60.63,"profit":true},{"date":"2020-12-31","value":92.42,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":88.55,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (150.57K) | (229.54K) | 78.76K | (219.91K) | (248.35K) | [{"date":"2019-12-31","value":-191.18,"profit":false},{"date":"2020-12-31","value":-291.44,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-279.21,"profit":false},{"date":"2023-12-31","value":-315.33,"profit":false}] |
Gross Margin | (Infinity%) | (291.44%) | 100.00% | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-291.44,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 14.13M | 20.69M | 38.74M | 41.34M | 29.79M | [{"date":"2019-12-31","value":34.18,"profit":true},{"date":"2020-12-31","value":50.05,"profit":true},{"date":"2021-12-31","value":93.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":72.06,"profit":true}] |
Operating Income | (13.58M) | (20.61M) | (45.47M) | (50.34M) | (29.79M) | [{"date":"2019-12-31","value":-1358355200,"profit":false},{"date":"2020-12-31","value":-2060648000,"profit":false},{"date":"2021-12-31","value":-4547312800,"profit":false},{"date":"2022-12-31","value":-5033903400,"profit":false},{"date":"2023-12-31","value":-2978550400,"profit":false}] |
Total Non-Operating Income/Expense | 443.75K | 42.13K | 7.13M | 11.64M | 3.83M | [{"date":"2019-12-31","value":3.81,"profit":true},{"date":"2020-12-31","value":0.36,"profit":true},{"date":"2021-12-31","value":61.26,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.91,"profit":true}] |
Pre-Tax Income | (13.68M) | (20.64M) | (31.64M) | (30.93M) | (28.13M) | [{"date":"2019-12-31","value":-1368402300,"profit":false},{"date":"2020-12-31","value":-2064093500,"profit":false},{"date":"2021-12-31","value":-3163824400,"profit":false},{"date":"2022-12-31","value":-3093064700,"profit":false},{"date":"2023-12-31","value":-2812829100,"profit":false}] |
Income Taxes | 299.42K | 7.40K | (6.91M) | (10.24M) | 5.00 | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":2.47,"profit":true},{"date":"2021-12-31","value":-2309.27,"profit":false},{"date":"2022-12-31","value":-3420.25,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (13.98M) | (20.65M) | (24.72M) | (20.69M) | (28.13M) | [{"date":"2019-12-31","value":-1398343900,"profit":false},{"date":"2020-12-31","value":-2064833300,"profit":false},{"date":"2021-12-31","value":-2472391600,"profit":false},{"date":"2022-12-31","value":-2068985900,"profit":false},{"date":"2023-12-31","value":-2812829600,"profit":false}] |
Income From Continuous Operations | (13.68M) | (20.64M) | (31.64M) | (30.93M) | (28.01M) | [{"date":"2019-12-31","value":-1368402300,"profit":false},{"date":"2020-12-31","value":-2064093500,"profit":false},{"date":"2021-12-31","value":-3163824400,"profit":false},{"date":"2022-12-31","value":-3093064700,"profit":false},{"date":"2023-12-31","value":-2800629300,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (13.68M) | (20.64M) | (31.64M) | (30.93M) | (28.13M) | [{"date":"2019-12-31","value":-1368402300,"profit":false},{"date":"2020-12-31","value":-2064093500,"profit":false},{"date":"2021-12-31","value":-3163824400,"profit":false},{"date":"2022-12-31","value":-3093064700,"profit":false},{"date":"2023-12-31","value":-2812829100,"profit":false}] |
EPS (Diluted) | (0.41) | (0.46) | (0.71) | (0.49) | (0.41) | [{"date":"2019-12-31","value":-41.01,"profit":false},{"date":"2020-12-31","value":-46.21,"profit":false},{"date":"2021-12-31","value":-70.97,"profit":false},{"date":"2022-12-31","value":-49,"profit":false},{"date":"2023-12-31","value":-41,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CRDL | |
---|---|
Cash Ratio | 2.28 |
Current Ratio | 2.49 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CRDL | |
---|---|
ROA (LTM) | -54.15% |
ROE (LTM) | -108.44% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CRDL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.40 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.60 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CRDL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1069.35 |
P/B | 14.95 |
Price/FCF | NM |
EV/R | 178.81 |
EV/Ebitda | 0.30 |
Cardiol Therapeutics Inc Class A (CRDL) share price today is $1.31
Yes, Indians can buy shares of Cardiol Therapeutics Inc Class A (CRDL) on Vested. To buy Cardiol Therapeutics Inc Class A from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRDL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cardiol Therapeutics Inc Class A (CRDL) via the Vested app. You can start investing in Cardiol Therapeutics Inc Class A (CRDL) with a minimum investment of $1.
You can invest in shares of Cardiol Therapeutics Inc Class A (CRDL) via Vested in three simple steps:
The 52-week high price of Cardiol Therapeutics Inc Class A (CRDL) is $3.12. The 52-week low price of Cardiol Therapeutics Inc Class A (CRDL) is $0.79.
The price-to-earnings (P/E) ratio of Cardiol Therapeutics Inc Class A (CRDL) is
The price-to-book (P/B) ratio of Cardiol Therapeutics Inc Class A (CRDL) is 14.95
The dividend yield of Cardiol Therapeutics Inc Class A (CRDL) is 0.00%
The market capitalization of Cardiol Therapeutics Inc Class A (CRDL) is $111.80M
The stock symbol (or ticker) of Cardiol Therapeutics Inc Class A is CRDL